New York University is a private research university in New York City. Chartered in 1831 by the New York State Legislature, NYU was founded by a group of New Yorkers led by then-Secretary of the Treasury Albert Gallatin.

During the past decade, NYU conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 5 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NYU" #1 sponsor was "AtriCure, Inc." with 1 trials, followed by "CSL Behring" with 1 trials sponsored, "Cochlear" with 1 trials sponsored, "IGM Biosciences, Inc." with 1 trials sponsored and "Medtronic - MITG" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NYU" #1 collaborator was "Ion Channel Innovations" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator, "National Institutes of Health (NIH)" with 1 trials as a collaborator, "Registrat-Mapi" with 1 trials as a collaborator and "The Cleveland Clinic" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "NYU" are "Antibody-mediated Rejection" (1 trials), "Barrett Esophagus" (1 trials), "Bronchial Neoplasm" (1 trials), "CIED Related Infection" (1 trials) and "Colorectal Cancer Screening" (1 trials). Many other conditions were trialed in "NYU" in a lesser frequency.

Most popular intervention types in "NYU" are "Device" (6 trials), "Drug" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "AtriClip" (1 trials), "C1-esterase inhibitor" (1 trials), "COLON Capsule endoscopy" (1 trials), "CP950 Sound Processor" (1 trials) and "Computed Tomographic Colonography" (1 trials). Other intervention names were less common.

The vast majority of trials in "NYU" are 11 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "NYU". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 7 completed trials in NYU, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in NYU, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".